Nonprocedural Symptomatic Infarction and In-Stent Restenosis After Intracranial Angioplasty and Stenting in the SAMMPRIS Trial

SAMMPRIS trial showed 30-day rate of stroke or death was higher in the PTAS group and than in the medical-management group.  In a follow-up study, investigators studied the frequency of symptomatic in-stent restenosis (ISR) and its contribution to nonprocedural symptomatic infarction.

In this study, 27 of 183 patients (14.8%) in the stenting group without a periprocedural primary end point had a symptomatic infarction and 16 (8.7%) had transient ischemic attack alone in the territory during a median follow-up of 35.0 months. Adequate vascular imaging to evaluate ISR was available in 24 patients with infarctions (showing ISR in 16 [66.7%]) and in 10 patients with TIA alone (showing ISR in 8 [80%]). The 1-, 2-, and 3-year rates (with 95% confidence limits) for symptomatic ISR in the SAMMPRIS stent cohort were 9.6% (6.1%–14.9%), 11.3% (7.5%–17.0%), and 14.0% (9.6%–20.2%), respectively.  The authors concluded that symptomatic ISR occurred in at least 1 of 7 patients in SAMMPRIS by 3 years of follow-up and was likely responsible for the majority of nonprocedural cerebral infarctions.

Contact Us Login Sitemap

American Association of Neurological Surgeons

Follow us on Facebook  Follow us on LinkedIn   Follow us on Twitter